Search
Selected Filter
Displaying 11–20 of 541 news results
-
Annual Funded Grants – CRISPR and Prime Editing Technologies
Research NewsFunded grants for CRISPR and prime editing approaches.
-
Foundation News
The free, online event at 7 p.m. ET on Tuesday, November 11, 2025, will feature presentations from patient advocate Jessie Wolinsky, retina specialist Sandeep Grover, MD, and clinical psychologist Ann Wagner, PhD, LP, ABPP.
-
Sepul Bio’s LCA10 RNA Therapy Moves into Phase 3 Clinical Trial
Research NewsThe emerging therapy improved vision for some participants in an earlier clinical trial.
-
Foundation Fighting Blindness Celebrates Blindness Awareness Month with #ShareYourVision Campaign
Foundation NewsThis social media campaign amplifies authentic stories from the blind and low vision community to highlight the spectrum of vision loss experiences.
-
Research News
Durable vision improvements were also observed out to 18 months for previously dosed adult patients in the trial.
-
Foundation Fighting Blindness Announces Over $9 Million in New Research Awards for FY2025
Research NewsThe Foundation Fighting Blindness is proud to announce the funding of 16 innovative research projects in Fiscal Year 2025, totaling over $9 million in new grants.
-
Agnes Gund – Renowned Philanthropist, Social Justice Champion, and Art Patron – Passes Away
Foundation NewsThe documentary “Aggie: An Incredible Story of Art and Justice” chronicles her story.
-
Letter to House Energy & Commerce Committee regarding H.R.1262, the Give Kids a Chance Act.
Advocacy Research NewsOn behalf of the Foundation Fighting Blindness and the millions of Americans impacted by inherited retinal diseases (IRDs), we urge you to advance H.R.1262, the Give Kids a Chance Act, and reauthorize the Rare Pediatric Disease Priority Review Voucher (PRV) Program.
-
Give Kids a Chance: Reauthorizing a Lifeline for Children’s Vision
Advocacy Foundation NewsThe House Energy & Commerce Committee is considering H.R.1262, the Give Kids a Chance Act, which would reauthorize the Rare Pediatric Disease Priority Review Voucher (PRV) Program.
-
Nacuity’s Antioxidative Therapy NACA Performs Encouragingly in Phase 1/2 Clinical Trial
Research NewsNACA is a gene-agnostic, oral medication designed to preserve vision in people with retinitis pigmentosa and Usher syndrome.
